RBC Capital initiates coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Outperform rating and a price target of $58.00.Analyst Randall ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE